Needham Maintains Buy on Veradermics, Raises Price Target to $164

Benzinga Newsdesk www.benzinga.com Positive 74.4%

Neg 0% Neu 0% Pos 74.4%

Needham analyst Serge Belanger maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $136 to $164.